Annamycin anthracycline data

ARNX presented Phase I results in cancer patients who had failed other therapies. As reported at the Denver meeting of the American Society of Clinical Oncology, multiple courses of the agent were evaluated in 30 patients. Doses were from 3-240 mg/m2, with up to 180 mg/m2 well tolerated. No evidence of cardiotoxicity or mucositis was found, and nausea and alopecia were minimal. The dose-limiting effect was thrombocytopenia (lowered platelets), which only occurred at the highest dose. ...